MALVERN, Pa., Oct. 25, 2024 /PRNewswire/ -- Endo, Inc. announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) in patients ...
MALVERN, Pa., March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or ...
MALVERN, Pa., Oct. 15, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that a presentation related to Peyronie's disease, or PD, and XIAFLEX® (collagenase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback